Skip to the answer

Amphetamine

Amphetamine is a CNS stimulant used across several products to treat ADHD, narcolepsy, and — in certain tablet formulations — short-term obesity management.

Brand names Adzenys ERAdzenys XRDyanavel XREvekeoEvekeo ODT +3 more
Drug classes Central Nervous System Stimulant
Rx Schedule CII Forms 4
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 29 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 5, 2026
Amphetamine at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Amphetamine is a stimulant, a usual first choice for ADHD that is also approved in some tablet forms for narcolepsy and short-term weight loss; it works by making nerve cells release more dopamine and norepinephrine and reabsorb less, has been on the U.S. market since about 1999, and is available as a generic. Most people tolerate it well, though appetite loss, dry mouth, and trouble sleeping (worse with late doses) are common. Its boxed warning is for abuse, misuse and addiction, and it raises heart rate and blood pressure and can trigger psychiatric symptoms, so report chest pain, an irregular heartbeat, or hallucinations promptly.

Clinical pearls

  • Vitamin C, fruit juice and some antacids can weaken its effect, while sodium bicarbonate can strengthen it.
  • Avoid alcohol with the extended-release forms, since alcohol can make them release the medicine far too quickly.
  • Never take it within 14 days of an MAO inhibitor antidepressant, and tell every prescriber about any other antidepressant.
  • Children taking it should have height and weight checked regularly, because stimulants can slow growth over time.
How we write & review this content — our editorial policy →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾

Amphetamine has a high potential for abuse, misuse, and addiction. Using it in ways other than prescribed — such as taking higher doses, snorting, or injecting — greatly raises the risk of overdose and death. Even when taken as prescribed, some people may develop a dependence or substance use disorder over time. Before starting, your prescriber should assess your personal risk. Store this medication in a secure, preferably locked place, do not share it with anyone, and safely dispose of any unused supply. If you notice signs of misuse — such as taking more than prescribed, craving the drug, or using it to get high — tell your doctor right away.

Read the full warning on DailyMed →
How you get itPrescription only
Comes asTablet, Orally disintegrating tablet, Extended-release tablet +1
Earliest FDA record1955
Companies listing it with the FDA16
FDA label last updatedMay 6, 2026
FDA’s strongest warning (boxed)Yes, read the warning

Patient information guide A plain-language walkthrough of Amphetamine, written from its FDA label.

What Amphetamine is used for

▾

Amphetamine is a CNS stimulant available in several products, each with its own approved uses:

  • ADHD (Attention Deficit Hyperactivity Disorder): Adzenys XR-ODT, Dyanavel XR, Amphetamine Extended-Release orally disintegrating tablets, Amphetamine Sulfate tablets, and Evekeo are all approved for ADHD. The extended-release products are approved for patients 6 years and older; the extended-release forms are not recommended under age 6.
  • Narcolepsy: Amphetamine Sulfate tablets and Evekeo are approved to treat narcolepsy (a condition causing uncontrollable daytime sleepiness).
  • Exogenous obesity (short-term): Amphetamine Sulfate tablets and Evekeo may be used short-term as part of a calorie-restricted weight-loss program for people who have not responded to other weight-loss approaches.

How Amphetamine works

▾

Amphetamine works by increasing the availability of two key brain chemicals: dopamine and norepinephrine. It blocks their reabsorption into nerve cells and triggers a greater release of these chemicals into the gaps between nerves. This boosts communication along pathways that regulate attention, impulse control, and alertness. The exact way this improves ADHD symptoms is not fully known, but these effects on brain chemistry are thought to be central to how it helps.

Amphetamine dosage

▾

All amphetamine forms are taken by mouth. Most formulations are taken once daily in the morning to avoid interfering with sleep. Evekeo and Amphetamine Sulfate tablets may be taken in divided doses throughout the day, with the first dose on waking and additional doses spaced 4 to 6 hours apart — again, avoiding late evening doses.

  • Most formulations can be taken with or without food; food may slightly delay onset but does not meaningfully change overall absorption.
  • Dose is always individualized — your prescriber will start low and adjust based on how you respond.
  • Different amphetamine products are not interchangeable milligram for milligram — never switch products without your prescriber's guidance.

Dosing details from the FDA-approved label

From the Amphetamine prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Pediatric patients (ages 6 to 17 years) - Amphetamine extended-release orally disintegrating tablets / Adzenys XR-ODT
    • Starting dose is 6.3 mg once daily in the morning
    • Increase in increments of 3.1 mg or 6.3 mg at weekly intervals
    • Maximum: 18.8 mg once daily for patients 6 to 12 years, and 12.5 mg once daily for patients 13 to 17 years
    • May be taken with or without food; allow tablet to disintegrate in saliva then swallow
  • Adults - Amphetamine extended-release orally disintegrating tablets / Adzenys XR-ODT
    • 12.5 mg once daily in the morning
    • May be taken with or without food; allow tablet to disintegrate in saliva then swallow
  • Switching from ADDERALL XR to amphetamine extended-release orally disintegrating tablets / Adzenys XR-ODT
    • Switch at the equivalent dose taken once daily: 3.1 mg = 5 mg, 6.3 mg = 10 mg, 9.4 mg = 15 mg, 12.5 mg = 20 mg, 15.7 mg = 25 mg, 18.8 mg = 30 mg ADDERALL XR
    • Do not substitute for other amphetamine products on a milligram-per-milligram basis; if switching from any other amphetamine product, discontinue it and titrate
  • Dyanavel XR (oral suspension and extended-release tablets)
    • Recommended starting dosage is 2.5 mg or 5 mg once daily in the morning
    • May be increased in increments of 2.5 mg to 10 mg per day every 4 to 7 days
    • Maximum: 20 mg daily
    • May be taken with or without food; shake suspension before use; tablets may be chewed or swallowed whole; suspension can be substituted with tablets on a milligram per milligram basis
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION May be taken with or without food. Allow tablet to disintegrate in saliva then swallow. ( 2.2 ) Pediatric patients (ages 6 to 17 years): Starting dose is 6.3 mg once daily in the morning. Maximum dose is 18.8 mg once daily for patients 6 to 12 years, and 12.5 mg once daily for patients 13 to 17 years. ( 2.3 ) Adults: 12.5 mg once daily in the morning. ( 2.4 ) To avoid substitution errors and overdosage, do not substitute for other amphetamine products on a milligram-per-milligram basis because of different amphetamine base compositions and differing pharmacokinetic profiles. ( 2.5 , 5.7 ) 2.1 Pre-treatment Screening Prior to treating patients with amphetamine extended-release orally disintegrating tablets, assess: for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) [see Warnings and Precautions ( 5.2 ) ] . the family history and clinically evaluate patients for motor or verbal tics or Tourette’s syndrome before initiating amphetamine extended-release orally disintegrating tablets [see Warnings and Precautions ( 5.9 )] . 2.2 General Administration Information Amphetamine extended-release orally disintegrating tablets may be taken orally with or without food. Individualize the dosage according to the therapeutic needs and response of the patient. Amphetamine extended-release orally disintegrating tablets should be taken as follows: The tablet should remain in the blister pack until the patient is ready to take it. The patient or caregiver should use dry hands to open the blister. Tear along the perforation, bend the blister where indicated and peel back the blister’s labeled backing to take out the tablet. The tablet should not be pushed through the foil. As soon as the blister is opened, the tablet should be removed and placed on the patient’s tongue. The whole tablet should be placed on the tongue and allowed to disintegrate without chewing or crushing. The tablet will disintegrate in saliva so that it can be swallowed. 2.3 Dosage Recommendations in Pediatric Patients The recommended starting dosage is 6.3 mg once daily in the morning. Increase in increments of 3.1 mg or 6.3 mg at weekly intervals.

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Amphetamine side effects

▾

The most commonly reported side effects of amphetamine include:

Common side effects

  • Loss of appetite
  • Trouble sleeping (insomnia)
  • Stomach pain or nausea
  • Dry mouth
  • Weight loss
  • Headache
  • Anxiety or nervousness
  • Increased heart rate
  • Stomach pain, nausea, or vomiting
  • Dizziness

When to get medical help

  • Call your doctor if you notice chest pain, irregular heartbeat, or shortness of breath
  • Seek help right away for signs of serotonin syndrome: agitation, hallucinations, rapid heart rate, high fever, stiff muscles, or loss of coordination
  • Tell your doctor if you develop new or worsening mood or behavior changes, hallucinations, or manic episodes
  • Contact your doctor if you notice numbness, color changes, or sores in fingers or toes (signs of circulation problems)
  • Get help immediately for signs of a severe allergic reaction: swelling of the face or throat, rash, or difficulty breathing
  • Tell your doctor about unusual or worsening tics or Tourette's syndrome symptoms
  • Seek emergency care for signs of overdose: dangerously high fever, seizures, confusion, or very high blood pressure

Serious reactions that need prompt medical attention include signs of serotonin syndrome (fever, muscle stiffness, rapid heart rate, confusion), new psychiatric symptoms (hallucinations, mania), circulation problems in fingers or toes, or signs of a severe allergic reaction such as facial swelling or difficulty breathing.

Amphetamine warnings and precautions

▾
  • Abuse, misuse, and addiction: Amphetamine has a high potential for abuse. Misuse — especially snorting or injecting — can cause overdose and death. Store it securely, don't share it, and dispose of unused medication properly.
  • Heart risks: Sudden death has occurred in patients with underlying heart conditions. People with structural heart defects, serious arrhythmia, or coronary artery disease should not take amphetamine. All patients should have blood pressure and heart rate monitored regularly.
  • Psychiatric effects: Amphetamine can trigger or worsen hallucinations, mania, or psychosis — even in people with no prior psychiatric history. Screen for bipolar disorder before starting.
  • Growth in children: Long-term use may slow height and weight gain in children. Pediatric patients should be monitored closely, and treatment may need to be paused if growth is affected.
  • Serotonin syndrome: A potentially life-threatening reaction can occur when amphetamine is combined with certain antidepressants or other serotonergic drugs.
  • Circulation problems: Raynaud's phenomenon (color changes, pain, or sores in fingers/toes) has been reported and should be watched for during treatment.

Amphetamine interactions

▾

Amphetamine interacts with a number of medications and substances — always give your pharmacist and prescriber a full list of everything you take:

  • MAO inhibitors (MAOIs): Extremely dangerous combination — can cause hypertensive crisis (a sudden, severe spike in blood pressure) and potentially fatal neurological effects. Do not take within 14 days of an MAOI.
  • Serotonergic drugs (SSRIs, SNRIs, triptans, tricyclic antidepressants, lithium, tramadol, St. John's Wort, buspirone, fentanyl, tryptophan): Increase the risk of serotonin syndrome when combined with amphetamine.
  • CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine, ritonavir): Can raise amphetamine blood levels, increasing both effects and side effect risk.
  • Acidifying agents (vitamin C, fruit juices, certain medications): Lower absorption and reduce amphetamine's effectiveness.
  • Alkalinizing agents (sodium bicarbonate, some diuretics): Increase amphetamine blood levels and may intensify its effects.
  • Blood pressure medications: Amphetamine may reduce how well they work.
  • Alcohol: High alcohol concentrations caused a large, rapid release of amphetamine from extended-release formulations in lab studies — avoid alcohol during treatment.

Interactions listed in the FDA-approved label

From the Amphetamine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • MAO inhibitors (MAOI antidepressants, metabolite of furazolidone): Slow amphetamine metabolism, potentiating amphetamines; this can cause headaches and other signs of hypertensive crisis, neurological toxic effects and malignant hyperpyrexia, sometimes fatal.
  • Serotonergic drugs: Concomitant use increases the risk of serotonin syndrome. Initiate with lower doses and monitor for serotonin syndrome, particularly at initiation or dosage increase; if it occurs, discontinue amphetamine and the serotonergic drug(s).
  • CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, quinidine, ritonavir): May increase amphetamine exposure and increase the risk of serotonin syndrome. Initiate with lower doses and monitor for serotonin syndrome at initiation and after a dosage increase; if it occurs, discontinue amphetamine and the CYP2D6 inhibitor.
  • Acidifying agents (GI and urinary, e.g., ascorbic acid, fruit juices, ammonium chloride): Lower absorption and/or increase urinary excretion of amphetamines, lowering blood levels and efficacy. Adjust dosage accordingly.
  • Alkalinizing agents (e.g., sodium bicarbonate, acetazolamide, some thiazides): Increase absorption and/or decrease urinary excretion of amphetamines, increasing blood levels and potentiating their action. Adjust dosage accordingly.
  • Tricyclic antidepressants: Amphetamines may enhance their activity; d-amphetamine with desipramine or protriptyline causes striking and sustained increases in brain d-amphetamine concentration and cardiovascular effects can be potentiated.
  • Adrenergic blockers: Adrenergic blockers are inhibited by amphetamines.
  • Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.
  • Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.
  • Chlorpromazine: Blocks dopamine and norepinephrine reuptake, inhibiting the central stimulant effects of amphetamine. Can be used to treat amphetamine poisoning.
Read the label’s full interactions text

Drug Interactions MAO inhibitors - MAOI antidepressants, as well as a metabolic of furazolidone, slow amphetamine metabolism. This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; this can cause headaches and other signs of hypertensive crisis. A variety of neurological toxic effects and malignant hyperpyrexia can occur, sometimes with fatal results. Serotonergic drugs - The concomitant use of amphetamine sulfate tablets and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during amphetamine sulfate tablets initiation or dosage increase. If serotonin syndrome occurs, discontinue amphetamine sulfate tablets and the concomitant serotonergic drug(s) ( see WARNINGS and PRECAUTIONS ). CYP2D6 inhibitors - The concomitant use of amphetamine sulfate tablets and CYP2D6 inhibitors may increase the exposure of amphetamine sulfate tablets compared to the use of the drug alone and increase the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome particularly during amphetamine sulfate tablets initiation and after a dosage increase. If serotonin syndrome occurs, discontinue amphetamine sulfate tablets and the CYP2D6 inhibitor ( see WARNINGS and OVERDOSAGE ). Examples of CYP2D6 Inhibitors include paroxetine and fluoxetine (also serotonergic drugs), quinidine, ritonavir. Acidifying agents - Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines. Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion. Both groups of agents lower blood levels and efficacy of amphetamines.

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿130 supplements and herbs with documented Amphetamine interactions, ranked by severity Check Amphetamine against a supplement or herb →

Before taking Amphetamine

▾
  • Tell your doctor if you have any heart disease, including irregular heartbeat, structural heart problems, or coronary artery disease — amphetamine is not safe for people with serious cardiac conditions.
  • Share any personal or family history of bipolar disorder, depression, psychosis, or suicidal behavior.
  • Mention any history of motor or verbal tics or Tourette's syndrome — amphetamine can worsen these.
  • Tell your doctor if you are pregnant: amphetamine may cause premature delivery, low birth weight, and withdrawal symptoms in newborns.
  • Breastfeeding is not recommended — amphetamine passes into breast milk and long-term effects on nursing infants are unknown.
  • Extended-release amphetamine products are not recommended for children under 6 years old; Evekeo and Amphetamine Sulfate tablets have separate age-related dosing guidance.
  • Tell your prescriber about all other medications, supplements, and herbal products you take — especially antidepressants, blood pressure drugs, and seizure medicines.
  • Do not take amphetamine if you are allergic to it or any of its ingredients, or if you have taken an MAOI in the past 14 days.

Amphetamine overdose

▾

Taking too much amphetamine can cause a rapid or irregular heartbeat, dangerously high or low blood pressure, high fever, seizures, confusion, hallucinations, and in severe cases, heart attack, stroke, or coma. If you suspect an overdose, call 911 or the Poison Help line at 1-800-222-1222 right away. Amphetamine cannot be removed from the body with dialysis, so emergency supportive care is the primary treatment.

What Amphetamine does in the body

▾

Amphetamine increases blood pressure and heart rate — on average, blood pressure rises by about 2 to 4 mmHg and heart rate by about 3 to 6 beats per minute, though some people may see larger increases. It also suppresses appetite, can reduce the urge to sleep, and stimulates the central nervous system. These effects stem from its action on norepinephrine and dopamine pathways throughout the brain and body.

How your body processes Amphetamine

▾

After taking an extended-release orally disintegrating tablet, amphetamine reaches peak blood levels in about 5 hours on an empty stomach; food delays peak levels by roughly 2 hours but does not significantly change total absorption. The drug is broken down in the liver (partly through an enzyme called CYP2D6) and cleared mainly through the urine — and how much is excreted depends heavily on urine acidity. The half-life (time for half the drug to leave the body) is about 11 hours in adults for d-amphetamine and about 9 to 10 hours in children ages 6 to 12; l-amphetamine stays in the body somewhat longer.

How to store Amphetamine

▾

Store at 20°C to 25º C (68°F to 77º F). Store ADZENYS XR-ODT blister packages in the rigid, plastic travel case provided after removal from the carton.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

130

Supplements & herbs that interact with Amphetamine

130 supplements and herbal products have documented interactions with Amphetamine in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 16
  • Moderate · 97
  • Minor · 17
ACTIVATED CHARCOAL Major BEER Major BITTER ORANGE Major BREWER'S YEAST Major COWHAGE Major EPHEDRA Major FEVER BARK Major PEYOTE Major +122 more
Every supplement checked against Amphetamine — ranked by severity The full interaction hub: 16 major · 97 moderate · 17 minor · every one linked to its full report. Check Amphetamine against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Amphetamine: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Amphetamine — the kind of thing our pharmacy team would talk through with you at the counter.

What conditions is amphetamine actually approved to treat?

▾
It depends on the specific product. Most amphetamine products — including Adzenys XR-ODT, Dyanavel XR, and the extended-release orally disintegrating tablets — are approved to treat ADHD in people 6 and older. Evekeo and Amphetamine Sulfate tablets also cover narcolepsy (a sleep disorder where you can't control falling asleep during the day) and short-term help with weight loss as part of a strict diet plan, for people who haven't had success with other approaches.

Is it okay to take this with food, or does it have to be on an empty stomach?

▾
You can take most amphetamine products with or without food — it won't meaningfully change how much you absorb. That said, eating (especially a high-fat meal) can delay when it kicks in by a couple of hours. Just try to take it consistently the same way each day, and always follow the instructions your prescriber gave you. One thing to avoid: alcohol, which can cause extended-release forms to release too much medication too quickly.

What side effects should I actually expect, and what would make me call my doctor?

▾
The most common side effects are loss of appetite, trouble sleeping, stomach aches, dry mouth, headache, and feeling a bit anxious or wound up — especially when you first start or after a dose increase. These often settle down. Call your doctor right away if you notice chest pain, a racing or irregular heartbeat, new mood changes like hallucinations or feeling manic, color changes or pain in your fingers or toes, or signs of a severe allergic reaction like facial swelling or trouble breathing.

I've heard this medication can be addictive. Should I be worried?

▾
This is a real concern worth taking seriously. Amphetamine does carry a genuine risk of misuse and addiction, which is why it's a controlled substance. When taken exactly as prescribed, the risk is much lower — but it's still important to store it safely (ideally locked up), never share it with anyone, and be honest with your doctor if you ever feel like you're craving it or taking more than prescribed. Your prescriber will also check in on this throughout your treatment.

Can my child take this, and are there any specific concerns for kids?

▾
The extended-release products are approved for children 6 and older. They're not recommended under age 6 because younger children absorb more of the drug and have more side effects at the same dose. One thing parents and prescribers watch closely is growth — amphetamine can slow weight gain and height over time in some kids, so your child's doctor will track height and weight at every visit. If growth seems to be falling behind, your doctor may suggest a medication break.

Are there any medications I absolutely cannot take with amphetamine?

▾
Yes — the most important one is any MAO inhibitor (MAOI), including certain antidepressants and the antibiotic linezolid. Combining amphetamine with an MAOI can cause a sudden, dangerous spike in blood pressure and can be life-threatening. You need to wait at least 14 days after stopping an MAOI before starting amphetamine (and vice versa). Also let your prescriber know about any antidepressants you take, since several types can interact with amphetamine and raise the risk of a serious reaction called serotonin syndrome.

Is Amphetamine available over the counter?

▾
No. Amphetamine is a prescription medicine: every Amphetamine product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

Is Amphetamine a controlled substance?

▾
Yes — Amphetamine is a federally controlled substance (Schedule II) in the United States, so how it is prescribed, refilled and dispensed is regulated by the DEA.

When was Amphetamine first available?

▾
The earliest FDA record we hold for Amphetamine is from 1955: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Amphetamine was first used.

Who makes Amphetamine?

▾
16 companies currently list Amphetamine products in the FDA's NDC Directory, including Bryant Ranch Prepack, Neos Therapeutics Brands, LLC, Neos Therapeutics, LP. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Amphetamine on HelloPharmacist

📊Amphetamine supplement interactions130 checked — ranked by severity 🌿Drug & Supplement CheckerAmphetamine vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Amphetamine NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Amphetamine Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Amphetamine forms and strengths (how it comes)

Amphetamine is available in 4 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Tablet

By mouth
Brands Evekeo
How this form is used
What it may be used for
  • Amphetamine Sulfate tablets and Evekeo are approved for ADHD as part of a broader treatment program including psychological and educational support
  • Amphetamine Sulfate tablets and Evekeo are approved for narcolepsy
  • Evekeo is approved as a short-term aid in a calorie-restricted weight-loss program for exogenous obesity in patients who have not responded to other treatments
  • Amphetamine Sulfate tablets are approved for exogenous obesity as a short-term adjunct to caloric restriction
Important instructions
  • Evekeo and Amphetamine Sulfate tablets are taken by mouth; the first dose is given on awakening, with any additional doses spaced 4 to 6 hours apart
  • Late evening doses should be avoided to prevent insomnia
  • Dose is adjusted individually based on response and tolerability — always follow your prescriber's guidance
Available strengths 2 strengths
5 mg 10 mg
87 FDA-listed product records ⓘ

Orally disintegrating tablet

By mouth
Brands Adzenys XR-ODT
How this form is used
What it may be used for
  • Adzenys XR-ODT is approved for the treatment of ADHD in patients 6 years and older
  • Amphetamine Extended-Release orally disintegrating tablets are approved for ADHD in patients 6 years and older
  • These extended-release orally disintegrating formulations are not recommended in children under 6 years of age
Important instructions
  • Adzenys XR-ODT and amphetamine extended-release orally disintegrating tablets should be kept in the blister pack until ready to use — open with dry hands, peel back the backing, and place the tablet on the tongue to dissolve, then swallow
  • These orally disintegrating tablets may be taken with or without food
  • Take once daily in the morning; do not substitute for other amphetamine products on a mg-per-mg basis
Available strengths 10 strengths
3.1 mg 5 mg/5 mg 6.3 mg 9.4 mg 10 mg/10 mg 12.5 mg
Show 4 more strengths Show fewer strengths
15 mg/15 mg 15.7 mg 18.8 mg 20 mg/20 mg
52 FDA-listed product records ⓘ

Extended-release tablet

By mouth
Brands Dyanavel Xr
How this form is used
What it may be used for
  • Dyanavel XR extended-release tablets are approved to treat ADHD in patients 6 years and older
  • Dyanavel XR is not recommended for children under 6 years of age
Important instructions
  • Dyanavel XR extended-release tablets may be chewed or swallowed whole
  • Dyanavel XR tablets are taken once daily in the morning, with or without food
  • Do not substitute Dyanavel XR for other amphetamine products on a mg-per-mg basis due to different formulations and absorption profiles
Available strengths 4 strengths
5 mg 10 mg 15 mg 20 mg
12 FDA-listed product records ⓘ

Extended-release oral suspension

By mouth
Brands Dyanavel XR
How this form is used
What it may be used for
  • Dyanavel XR is approved to treat ADHD in patients 6 years and older
  • Dyanavel XR is not recommended for children under 6 years of age
Important instructions
  • Dyanavel XR oral suspension should be shaken well before each dose
  • Dyanavel XR is taken once daily in the morning, with or without food
  • Dyanavel XR oral suspension can be switched to Dyanavel XR tablets milligram for milligram, but do not substitute for other amphetamine products on a mg-per-mg basis
Available strengths 1 strength
2.5 mg/mL
3 FDA-listed product records ⓘ

Amphetamine on the U.S. market: products, makers and brands

How Amphetamine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

16 companies list 58 Amphetamine product records with the FDA, mostly as tablet, orally disintegrating tablet, extended-release tablet; the earliest marketing or approval year on record is 1955. Brand names on the directory include Adzenys ER, Adzenys XR, Dyanavel XR and 5 more; the rest are generics.

4
Dose forms ⓘ
16
Labelers (makers, repackagers, distributors)
6
Brand names
58
FDA-listed product records ⓘ
1955
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (10) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Bryant Ranch Prepack22%
Neos Therapeutics Brands, LLC10%
Neos Therapeutics, LP10%
Teva Pharmaceuticals, Inc.10%
NextWave Pharmaceuticals, Inc9%
Amici Pharma, Inc.3%
Other makers34%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Amphetamine is used (Medicaid data)

A general measure of how commonly Amphetamine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Amphetamine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

93,374
Medicaid prescriptions filled (Q1–Q4 2025)
$38.6M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Amphetamine prescribed? Of the 1,601 medications we measure, Amphetamine ranks #521 by Medicaid prescriptions — more than 67% of them.

Where Amphetamine ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #521 of 1,601
#516 Doxylamine and Pyridox... 97,428 Rx #517 Dolutegravir 95,552 Rx #518 Cilostazol 94,961 Rx #519 Azelaic Acid Topical 94,548 Rx #520 Mycophenolic Acid 94,168 Rx #521 Amphetamine 93,374 Rx #522 Ulipristal 93,222 Rx #523 Imiquimod Topical 92,281 Rx #524 Nebivolol 91,607 Rx #525 Orphenadrine 91,158 Rx #526 Megestrol 91,036 Rx

Utilization by Amphetamine product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 2.5 mg/mL 24 hr extended release suspension is the most-dispensed Amphetamine product — about 34% of these Medicaid prescriptions.

24 HR amphetamine 2.5 MG/ML Extended Release Suspension Most dispensed

32,028 Medicaid prescriptions (Q1–Q4 2025) 34% of Amphetamine prescriptions shown $12.6M gross reimbursement (before rebates) ≈ $392 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1720586

24 HR amphetamine 20 MG Extended Release Oral Tablet

12,511 Medicaid prescriptions (Q1–Q4 2025) 13% of Amphetamine prescriptions shown $5.5M gross reimbursement (before rebates) ≈ $438 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2585468

24 HR amphetamine 10 MG Extended Release Oral Tablet

10,868 Medicaid prescriptions (Q1–Q4 2025) 12% of Amphetamine prescriptions shown $4.7M gross reimbursement (before rebates) ≈ $435 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2585460

24 HR amphetamine 15 MG Extended Release Oral Tablet

9,248 Medicaid prescriptions (Q1–Q4 2025) 10% of Amphetamine prescriptions shown $4M gross reimbursement (before rebates) ≈ $434 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2585462

24 HR amphetamine 5 MG Extended Release Oral Tablet

6,632 Medicaid prescriptions (Q1–Q4 2025) 7% of Amphetamine prescriptions shown $1.5M gross reimbursement (before rebates) ≈ $233 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2585473

24 HR amphetamine 18.8 MG Extended Release Oral Tablet

5,027 Medicaid prescriptions (Q1–Q4 2025) 5% of Amphetamine prescriptions shown $2.8M gross reimbursement (before rebates) ≈ $553 per prescription (gross)

Summed across the 2 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1739819

24 HR amphetamine 12.5 MG Extended Release Oral Tablet

4,408 Medicaid prescriptions (Q1–Q4 2025) 5% of Amphetamine prescriptions shown $2.4M gross reimbursement (before rebates) ≈ $552 per prescription (gross)

Summed across the 2 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1739803

24 HR amphetamine 15.7 MG Extended Release Oral Tablet

3,194 Medicaid prescriptions (Q1–Q4 2025) 3% of Amphetamine prescriptions shown $1.7M gross reimbursement (before rebates) ≈ $539 per prescription (gross)

Summed across the 2 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1739813

24 HR amphetamine 9.4 MG Extended Release Oral Tablet

3,114 Medicaid prescriptions (Q1–Q4 2025) 3% of Amphetamine prescriptions shown $1.6M gross reimbursement (before rebates) ≈ $529 per prescription (gross)

Summed across the 2 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1739837

amphetamine sulfate 10 MG Oral Tablet

2,708 Medicaid prescriptions (Q1–Q4 2025) 3% of Amphetamine prescriptions shown $132,646 gross reimbursement (before rebates) ≈ $49 per prescription (gross)

Summed across the 4 of 24 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1600695

24 HR amphetamine 6.3 MG Extended Release Oral Tablet

2,311 Medicaid prescriptions (Q1–Q4 2025) 2% of Amphetamine prescriptions shown $1.2M gross reimbursement (before rebates) ≈ $532 per prescription (gross)

Summed across the 2 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1739831

amphetamine sulfate 5 MG Oral Tablet

731 Medicaid prescriptions (Q1–Q4 2025) <1% of Amphetamine prescriptions shown $30,440 gross reimbursement (before rebates) ≈ $42 per prescription (gross)

Summed across the 4 of 23 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 884655

24 HR amphetamine 3.1 MG Extended Release Oral Tablet

594 Medicaid prescriptions (Q1–Q4 2025) <1% of Amphetamine prescriptions shown $335,730 gross reimbursement (before rebates) ≈ $565 per prescription (gross)

Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1739825

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Amphetamine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 24 of 78 listed Amphetamine NDCs with Medicaid activity.

Compare Amphetamine products

A representative set of FDA-listed product records for Amphetamine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 58 of 58 products — FDA National Drug Code Directory. See every product, package size and price: browse all 58 Amphetamine NDCs →

Amphetamine recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Amphetamine recalls since July 2021.

✅No Amphetamine recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Amphetamine RxCUI 725 4 dose forms · 18 strengths
  1. Dose form (SCDF) Disintegrating Oral Tablet RxCUI 2118894 In current FDA listings
    Clinical drug / strength (SCD) sulfate 10 MG RxCUI 2118896 sulfate 15 MG RxCUI 2118898 sulfate 20 MG RxCUI 2118900 sulfate 5 MG RxCUI 2118895
  2. Dose form (SCDF) Extended Release Oral Tablet RxCUI 1739802 In current FDA listings
    Clinical drug / strength (SCD) 24 HR amphetamine 10 MG RxCUI 2585460 24 HR amphetamine 12.5 MG RxCUI 1739803 24 HR amphetamine 15 MG RxCUI 2585462 24 HR amphetamine 15.7 MG RxCUI 1739813 24 HR amphetamine 18.8 MG RxCUI 1739819 24 HR amphetamine 20 MG RxCUI 2585468 24 HR amphetamine 3.1 MG RxCUI 1739825 24 HR amphetamine 5 MG RxCUI 2585473 24 HR amphetamine 6.3 MG RxCUI 1739831 24 HR amphetamine 9.4 MG RxCUI 1739837
  3. Dose form (SCDF) Extended Release Suspension RxCUI 1720585 In current FDA listings
    Clinical drug / strength (SCD) 1.25 MG/ML RxCUI 1945840 24 HR amphetamine 2.5 MG/ML RxCUI 1720586
  4. Dose form (SCDF) Oral Tablet RxCUI 370893 In current FDA listings
    Clinical drug / strength (SCD) sulfate 10 MG RxCUI 1600695 sulfate 5 MG RxCUI 884655

Look up RxCUI 725 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

💵 What Amphetamine costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Tablet · Oral 10 mg $0.409 per tablet NDC details & price history
Tablet · Oral 5 mg $0.425 per tablet NDC details & price history
Tablet, Orally Disintegrating · Oral 12.5 mg $15.96 per tablet NDC details & price history
Tablet, Orally Disintegrating · Oral 18.8 mg $15.61 per tablet NDC details & price history
Tablet, Orally Disintegrating · Oral 15.7 mg $15.93 per tablet NDC details & price history
Tablet, Orally Disintegrating · Oral 9.4 mg $16.22 per tablet NDC details & price history
Tablet, Orally Disintegrating · Oral 6.3 mg $16.07 per tablet NDC details & price history
Tablet, Orally Disintegrating · Oral 3.1 mg $15.84 per tablet NDC details & price history
Tablet, Extended Release · Oral 20 mg $14.79 per tablet NDC details & price history
Tablet, Extended Release · Oral 5 mg $7.85 per tablet NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Amphetamine brand names

Amphetamine is sold under 8 brand names in the FDA directory — Adzenys ER, Adzenys XR, Dyanavel XR, Evekeo and others. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Adzenys ER Adzenys XR Dyanavel XR Evekeo Evekeo ODT Dyanavel Adzenys Adzenys XR-ODT

Who makes Amphetamine: manufacturers and labelers

16 companies list Amphetamine products with the FDA. By number of product records, the largest are Bryant Ranch Prepack, Neos Therapeutics Brands, LLC, Neos Therapeutics, LP. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Bryant Ranch Prepack 13 Neos Therapeutics Brands, LLC 6 Neos Therapeutics, LP 6 Teva Pharmaceuticals, Inc. 6 NextWave Pharmaceuticals, Inc 5 Amici Pharma, Inc. 2 Amneal Pharmaceuticals NY LLC 2 Aurolife Pharma, LLC 2 Azurity Pharmaceuticals, Inc. 2 Dr. Reddy's Laboratories Inc 2 Epic Pharma LLC 2 Granules Pharmaceuticals Inc. 2 Lannett Company, Inc. 2 Solco Healthcare US, LLC 2 SpecGx LLC 2 Wilshire Pharmaceuticals, Inc. 2

Amphetamine drug class (RxNorm)

Amphetamine belongs to the Central Nervous System Stimulant class.

Pharmacologic class Central Nervous System Stimulant
Drug family (ATC) Centrally acting sympathomimetics

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Amphetamine page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective May 6, 2026
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Amphetamine.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Amphetamine after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
29
Finished products in the current FDA directory
58
Companies listing them (makers, repackagers, distributors)
16
FDA labeler codes behind them ⓘ
18
Linked representative label ⓘ
Neos Therapeutics Brands, LLC
Linked label effective
May 6, 2026
Composite sections available
28
Linked SPL Set ID
c1179269-00b5-48ea-972d-31e614e99b7e
Linked SPL Document ID
512c5af5-6bf8-ace1-e063-6394a90ad807
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Neos Therapeutics Brands, LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →